FDA: Merck's Gardasil stops genital warts in boys

Sep 04, 2009 By MATTHEW PERRONE , AP Business Writer

(AP) -- Merck's blockbuster vaccine Gardasil, which is already used to prevent cervical cancer in women, also stops viruses that cause genital warts in men, the Food and Drug Administration said Friday.

In documents posted online, the FDA said the prevented in males 90 percent of the time.

The vaccine works by blocking the two strains of the , or HPV, which causes irregular growths and rare types of cancer in male genitals.

Merck has asked the FDA to approve Gardasil for boys and men ages 9 to 26.

A panel of vaccine advisers will weigh in on the new use next week. The FDA is not required to follow the group's advice, though it usually does.

A 4,000-patient study conducted by Merck compared patients taking Gardasil to patients taking a sham treatment for three years.

Merck had originally asked the FDA to approve the vaccine for prevention of both genital warts and precancerous growths on the penis and anus. However, reviewers said the number of those growths was too small to evaluate.

The Whitehouse Station, N.J.-based company and the FDA agreed to "evaluate a less broad indication focusing only on genital warts," the FDA documents state.

Side effects with the vaccine were mild, such as pain and swelling at the injection site.

Gardasil was approved for women in 2006 and had sales over $1 billion last year.

About 6 million people in the U.S. each year contract HPV, which usually causes no symptoms and clears up by itself. While there are about 40 strains of the virus that are spread through sexual contact, only about 15 cause cancer in men and women.

Cancer of the penis and anus are extremely rare, with less than 2,000 cases reported annually.

"When I talk to people I often say the burden of these diseases in men is understated and unrecognized," said Dr. Richard Haupt, Merck's head researcher for Gardasil. "Gardasil is highly efficacious and we should see an impact on men's health because of that."

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Blood test for yeast infections approved

add to favorites email to friend print save as pdf

Related Stories

FDA considers expanded use of HPV vaccine

Mar 20, 2008

Pharmaceutical manufacturer Merck & Co. Inc. said the U.S. Food and Drug Administration will consider expanding the use of its cervical cancer vaccine.

New HPV vaccine under study

Nov 19, 2007

A new vaccine against nine of the most harmful strains of human papillomavirus is under study at the Medical College of Georgia.

Some men want girls' vaccine, too

Feb 23, 2007

Some British gay men want to be vaccinated with the drug approved to protect girls from cervical cancer, saying it could help them, too.

The HPV vaccine that doctors would recommend

Oct 24, 2008

Despite the government's decision to choose the vaccine Cervarix for the UK human papillomavirus (HPV) vaccination programme, every doctor I have spoken to has chosen Gardisal for their own children, says a doctor on bmj.com ...

HPV vaccine reduces abnormal pap test results

Mar 10, 2008

In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine, according new research. The findings show the approved anti-HPV agent appears to prevent the development of cell ...

Recommended for you

Blood test for yeast infections approved

5 hours ago

(HealthDay)—The first blood test to detect five strains of yeast that cause rare blood infections in people with weakened immune systems has been approved by the U.S. Food and Drug Administration.

Discount generic drug programs grow over time

Sep 22, 2014

Generic discount drug programs (GDDPs, which charge nominal fees to fill prescriptions) have grown over time and their initial lower use by racial/ethnic minorities has evaporated, writes author Song Hee Hong, Ph.D., of the ...

Seniors successfully withdraw from meds

Sep 19, 2014

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

User comments : 0